BioCentury
ARTICLE | Clinical News

Myocet doxorubicin: Phase I/II data

February 9, 2009 8:00 AM UTC

In the open-label, Spanish Phase I/II SOLTI trial in 69 patients, Myocet plus Herceptin trastuzumab and paclitaxel produced an overall response rate of 98%, including a complete response rate of 54% ...